To investigate systematic metabolic biomarkers for early diagnosis of glucose-well-controlled DM patients who still developed diabetic retinopathy (GW-DR) and explore potential biomarker-based precise
Sequence and structural alterations together with tumor mutation burden (TMB) and microsatellite instability (MSI) have been identified as biomarkers for the determination of response to targeted and